APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rheumatic Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Rheumatic Disease Drugs Industry Growth and Trends Forecast to 2032

23 December 2025114 pages

Choose your research edition.

Industry ResearchRheumatic Disease Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Rheumatic Disease Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Rheumatic Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rheumatic Disease Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Rheumatic Disease Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

According to APO Research, the global Rheumatic Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Rheumatic Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Rheumatic Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rheumatic Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Rheumatic Disease Drugs market include Simcere, WuXi AppTec, Sanofi, Johnson & Johnson, Roche, Eli Lilly and Company, ALPHAMAB ONCOLOGY, Hengrui and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Rheumatic Disease Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Rheumatic Disease Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Rheumatic Disease Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Rheumatic Disease Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Rheumatic Disease Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Rheumatic Disease Drugs Market by Company

Simcere

WuXi AppTec

Sanofi

Johnson & Johnson

Roche

Eli Lilly and Company

ALPHAMAB ONCOLOGY

Hengrui

Pfizer

Henlius

Bristol-Myers Squibb

Amgen

AbbVie

UCB

Mitsubishi Tanabe Pharma Corporation

IQVIA

Boehringer-Ingelheim

Aprazer

Rheumatic Disease Drugs Segment by Type

DMARDs

JAK Inhibitors

Biologics

Others

Rheumatic Disease Drugs Segment by Application

Hospital

Clinic

Others

Rheumatic Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatic Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rheumatic Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatic Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Rheumatic Disease Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Rheumatic Disease Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Rheumatic Disease Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Rheumatic Disease Drugs Market Share by Region (2021-2026) Table 4. Global Rheumatic Disease Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Rheumatic Disease Drugs Market Share by Region (2027-2032) Table 6. Global Rheumatic Disease Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Rheumatic Disease Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Rheumatic Disease Drugs Market Size Share by Type (2021-2026) Table 9. Global Rheumatic Disease Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Rheumatic Disease Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Rheumatic Disease Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Rheumatic Disease Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Rheumatic Disease Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Rheumatic Disease Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Rheumatic Disease Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Rheumatic Disease Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Rheumatic Disease Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Rheumatic Disease Drugs Market Size Share by Application (2021-2026) Table 24. Global Rheumatic Disease Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Rheumatic Disease Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Rheumatic Disease Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Rheumatic Disease Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Rheumatic Disease Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Rheumatic Disease Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Rheumatic Disease Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Rheumatic Disease Drugs Industry Trends Table 37. Rheumatic Disease Drugs Industry Drivers Table 38. Rheumatic Disease Drugs Industry Opportunities and Challenges Table 39. Rheumatic Disease Drugs Industry Restraints Table 40. Global Rheumatic Disease Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Rheumatic Disease Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Rheumatic Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Rheumatic Disease Drugs Key Company Headquarters & Area Served Table 44. Global Rheumatic Disease Drugs Company, Product Type & Application Table 45. Global Rheumatic Disease Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Rheumatic Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Simcere Company Information Table 49. Simcere Business Overview Table 50. Simcere Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Simcere Rheumatic Disease Drugs Product Portfolio Table 52. Simcere Recent Development Table 53. WuXi AppTec Company Information Table 54. WuXi AppTec Business Overview Table 55. WuXi AppTec Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. WuXi AppTec Rheumatic Disease Drugs Product Portfolio Table 57. WuXi AppTec Recent Development Table 58. Sanofi Company Information Table 59. Sanofi Business Overview Table 60. Sanofi Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Sanofi Rheumatic Disease Drugs Product Portfolio Table 62. Sanofi Recent Development Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Rheumatic Disease Drugs Product Portfolio Table 67. Johnson & Johnson Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Roche Rheumatic Disease Drugs Product Portfolio Table 72. Roche Recent Development Table 73. Eli Lilly and Company Company Information Table 74. Eli Lilly and Company Business Overview Table 75. Eli Lilly and Company Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Eli Lilly and Company Rheumatic Disease Drugs Product Portfolio Table 77. Eli Lilly and Company Recent Development Table 78. ALPHAMAB ONCOLOGY Company Information Table 79. ALPHAMAB ONCOLOGY Business Overview Table 80. ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Product Portfolio Table 82. ALPHAMAB ONCOLOGY Recent Development Table 83. Hengrui Company Information Table 84. Hengrui Business Overview Table 85. Hengrui Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Hengrui Rheumatic Disease Drugs Product Portfolio Table 87. Hengrui Recent Development Table 88. Pfizer Company Information Table 89. Pfizer Business Overview Table 90. Pfizer Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Pfizer Rheumatic Disease Drugs Product Portfolio Table 92. Pfizer Recent Development Table 93. Henlius Company Information Table 94. Henlius Business Overview Table 95. Henlius Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Henlius Rheumatic Disease Drugs Product Portfolio Table 97. Henlius Recent Development Table 98. Bristol-Myers Squibb Company Information Table 99. Bristol-Myers Squibb Business Overview Table 100. Bristol-Myers Squibb Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Bristol-Myers Squibb Rheumatic Disease Drugs Product Portfolio Table 102. Bristol-Myers Squibb Recent Development Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Amgen Rheumatic Disease Drugs Product Portfolio Table 107. Amgen Recent Development Table 108. AbbVie Company Information Table 109. AbbVie Business Overview Table 110. AbbVie Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. AbbVie Rheumatic Disease Drugs Product Portfolio Table 112. AbbVie Recent Development Table 113. UCB Company Information Table 114. UCB Business Overview Table 115. UCB Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. UCB Rheumatic Disease Drugs Product Portfolio Table 117. UCB Recent Development Table 118. Mitsubishi Tanabe Pharma Corporation Company Information Table 119. Mitsubishi Tanabe Pharma Corporation Business Overview Table 120. Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Product Portfolio Table 122. Mitsubishi Tanabe Pharma Corporation Recent Development Table 123. IQVIA Company Information Table 124. IQVIA Business Overview Table 125. IQVIA Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. IQVIA Rheumatic Disease Drugs Product Portfolio Table 127. IQVIA Recent Development Table 128. Boehringer-Ingelheim Company Information Table 129. Boehringer-Ingelheim Business Overview Table 130. Boehringer-Ingelheim Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Boehringer-Ingelheim Rheumatic Disease Drugs Product Portfolio Table 132. Boehringer-Ingelheim Recent Development Table 133. Aprazer Company Information Table 134. Aprazer Business Overview Table 135. Aprazer Rheumatic Disease Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Aprazer Rheumatic Disease Drugs Product Portfolio Table 137. Aprazer Recent Development Table 138. North America Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Rheumatic Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Rheumatic Disease Drugs Market Share by Country (2021-2026) Table 141. North America Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Rheumatic Disease Drugs Market Share Forecast by Country (2027-2032) Table 143. Europe Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Rheumatic Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Rheumatic Disease Drugs Market Share by Country (2021-2026) Table 146. Europe Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Rheumatic Disease Drugs Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Rheumatic Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Rheumatic Disease Drugs Market Share by Country (2021-2026) Table 151. Asia-Pacific Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Rheumatic Disease Drugs Market Share Forecast by Country (2027-2032) Table 153. Latin America Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Rheumatic Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Rheumatic Disease Drugs Market Share by Country (2021-2026) Table 156. Latin America Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Rheumatic Disease Drugs Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Rheumatic Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Rheumatic Disease Drugs Market Share by Country (2021-2026) Table 161. Middle East & Africa Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Rheumatic Disease Drugs Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Rheumatic Disease Drugs Product Image Figure 3. Global Rheumatic Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Rheumatic Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Rheumatic Disease Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Rheumatic Disease Drugs Market Share by Region (2021-2032) Figure 7. North America Rheumatic Disease Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Rheumatic Disease Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Rheumatic Disease Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Rheumatic Disease Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Rheumatic Disease Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. DMARDs Image Figure 13. Global DMARDs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. JAK Inhibitors Image Figure 15. Global JAK Inhibitors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Biologics Image Figure 17. Global Biologics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Others Image Figure 19. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Rheumatic Disease Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Rheumatic Disease Drugs Market Share by Type 2025 VS 2032 Figure 22. North America Rheumatic Disease Drugs Market Size Share by Type (2021-2032) Figure 23. Europe Rheumatic Disease Drugs Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Rheumatic Disease Drugs Market Size Share by Type (2021-2032) Figure 25. Latin America Rheumatic Disease Drugs Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Rheumatic Disease Drugs Market Size Share by Type (2021-2032) Figure 27. Hospital Image Figure 28. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Clinic Image Figure 30. Global Clinic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Others Image Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Rheumatic Disease Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Rheumatic Disease Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Rheumatic Disease Drugs Market Size Share by Application (2021-2032) Figure 36. Europe Rheumatic Disease Drugs Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Rheumatic Disease Drugs Market Size Share by Application (2021-2032) Figure 38. Latin America Rheumatic Disease Drugs Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Rheumatic Disease Drugs Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Rheumatic Disease Drugs Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Rheumatic Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Rheumatic Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Rheumatic Disease Drugs Market Share by Country (2021-2032) Figure 45. Europe Rheumatic Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Rheumatic Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Rheumatic Disease Drugs Market Share by Country (2021-2032) Figure 48. Asia-Pacific Rheumatic Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Rheumatic Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Rheumatic Disease Drugs Market Share by Country (2021-2032) Figure 51. Latin America Rheumatic Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Rheumatic Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Rheumatic Disease Drugs Market Share by Country (2021-2032) Figure 54. Middle East & Africa Rheumatic Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Rheumatic Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Rheumatic Disease Drugs Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • DMARDs
  • JAK Inhibitors
  • Biologics
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Simcere
  • WuXi AppTec
  • Sanofi
  • Johnson & Johnson
  • Roche
  • Eli Lilly and Company
  • ALPHAMAB ONCOLOGY
  • Hengrui
  • Pfizer
  • Henlius
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • UCB
  • Mitsubishi Tanabe Pharma Corporation
  • IQVIA
  • Boehringer-Ingelheim
  • Aprazer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Rheumatic Disease Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Rheumatic Disease Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Rheumatic Disease Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Rheumatic Disease Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Rheumatic Disease Drugs Market Size (2021-2032)
  8. 1.5.1 North America Rheumatic Disease Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Rheumatic Disease Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Rheumatic Disease Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Rheumatic Disease Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Rheumatic Disease Drugs Market Size Growth Rate (2021-2032)
2 Rheumatic Disease Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 DMARDs
  3. 2.1.2 JAK Inhibitors
  4. 2.1.3 Biologics
  5. 2.1.4 Others
  6. 2.2 Global Rheumatic Disease Drugs Market Size by Type
  7. 2.2.1 Global Rheumatic Disease Drugs Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Rheumatic Disease Drugs Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Rheumatic Disease Drugs Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Rheumatic Disease Drugs Market Size by Regions
  11. 2.3.1 North America Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Rheumatic Disease Drugs Market Size Breakdown by Type (2021-2026)
3 Rheumatic Disease Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Clinic
  4. 3.1.3 Others
  5. 3.2 Global Rheumatic Disease Drugs Market Size by Application
  6. 3.2.1 Global Rheumatic Disease Drugs Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Rheumatic Disease Drugs Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Rheumatic Disease Drugs Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Rheumatic Disease Drugs Market Size by Regions
  10. 3.3.1 North America Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Rheumatic Disease Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Rheumatic Disease Drugs Industry Trends
  2. 4.2 Rheumatic Disease Drugs Industry Drivers
  3. 4.3 Rheumatic Disease Drugs Industry Opportunities and Challenges
  4. 4.4 Rheumatic Disease Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Rheumatic Disease Drugs Revenue (2021-2026)
  2. 5.2 Global Rheumatic Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Rheumatic Disease Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Rheumatic Disease Drugs Company, Product Type & Application
  5. 5.5 Global Rheumatic Disease Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Rheumatic Disease Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Rheumatic Disease Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Rheumatic Disease Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Simcere
  2. 6.1.1 Simcere Company Information
  3. 6.1.2 Simcere Business Overview
  4. 6.1.3 Simcere Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Simcere Rheumatic Disease Drugs Product Portfolio
  6. 6.1.5 Simcere Recent Developments
  7. 6.2 WuXi AppTec
  8. 6.2.1 WuXi AppTec Company Information
  9. 6.2.2 WuXi AppTec Business Overview
  10. 6.2.3 WuXi AppTec Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 WuXi AppTec Rheumatic Disease Drugs Product Portfolio
  12. 6.2.5 WuXi AppTec Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Rheumatic Disease Drugs Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Johnson & Johnson
  20. 6.4.1 Johnson & Johnson Company Information
  21. 6.4.2 Johnson & Johnson Business Overview
  22. 6.4.3 Johnson & Johnson Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Johnson & Johnson Rheumatic Disease Drugs Product Portfolio
  24. 6.4.5 Johnson & Johnson Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Roche Rheumatic Disease Drugs Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Eli Lilly and Company
  32. 6.6.1 Eli Lilly and Company Company Information
  33. 6.6.2 Eli Lilly and Company Business Overview
  34. 6.6.3 Eli Lilly and Company Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly and Company Rheumatic Disease Drugs Product Portfolio
  36. 6.6.5 Eli Lilly and Company Recent Developments
  37. 6.7 ALPHAMAB ONCOLOGY
  38. 6.7.1 ALPHAMAB ONCOLOGY Company Information
  39. 6.7.2 ALPHAMAB ONCOLOGY Business Overview
  40. 6.7.3 ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Product Portfolio
  42. 6.7.5 ALPHAMAB ONCOLOGY Recent Developments
  43. 6.8 Hengrui
  44. 6.8.1 Hengrui Company Information
  45. 6.8.2 Hengrui Business Overview
  46. 6.8.3 Hengrui Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Hengrui Rheumatic Disease Drugs Product Portfolio
  48. 6.8.5 Hengrui Recent Developments
  49. 6.9 Pfizer
  50. 6.9.1 Pfizer Company Information
  51. 6.9.2 Pfizer Business Overview
  52. 6.9.3 Pfizer Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Rheumatic Disease Drugs Product Portfolio
  54. 6.9.5 Pfizer Recent Developments
  55. 6.10 Henlius
  56. 6.10.1 Henlius Company Information
  57. 6.10.2 Henlius Business Overview
  58. 6.10.3 Henlius Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Henlius Rheumatic Disease Drugs Product Portfolio
  60. 6.10.5 Henlius Recent Developments
  61. 6.11 Bristol-Myers Squibb
  62. 6.11.1 Bristol-Myers Squibb Company Information
  63. 6.11.2 Bristol-Myers Squibb Business Overview
  64. 6.11.3 Bristol-Myers Squibb Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Bristol-Myers Squibb Rheumatic Disease Drugs Product Portfolio
  66. 6.11.5 Bristol-Myers Squibb Recent Developments
  67. 6.12 Amgen
  68. 6.12.1 Amgen Company Information
  69. 6.12.2 Amgen Business Overview
  70. 6.12.3 Amgen Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Amgen Rheumatic Disease Drugs Product Portfolio
  72. 6.12.5 Amgen Recent Developments
  73. 6.13 AbbVie
  74. 6.13.1 AbbVie Company Information
  75. 6.13.2 AbbVie Business Overview
  76. 6.13.3 AbbVie Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 AbbVie Rheumatic Disease Drugs Product Portfolio
  78. 6.13.5 AbbVie Recent Developments
  79. 6.14 UCB
  80. 6.14.1 UCB Company Information
  81. 6.14.2 UCB Business Overview
  82. 6.14.3 UCB Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 UCB Rheumatic Disease Drugs Product Portfolio
  84. 6.14.5 UCB Recent Developments
  85. 6.15 Mitsubishi Tanabe Pharma Corporation
  86. 6.15.1 Mitsubishi Tanabe Pharma Corporation Company Information
  87. 6.15.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  88. 6.15.3 Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Product Portfolio
  90. 6.15.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  91. 6.16 IQVIA
  92. 6.16.1 IQVIA Company Information
  93. 6.16.2 IQVIA Business Overview
  94. 6.16.3 IQVIA Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 IQVIA Rheumatic Disease Drugs Product Portfolio
  96. 6.16.5 IQVIA Recent Developments
  97. 6.17 Boehringer-Ingelheim
  98. 6.17.1 Boehringer-Ingelheim Company Information
  99. 6.17.2 Boehringer-Ingelheim Business Overview
  100. 6.17.3 Boehringer-Ingelheim Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Boehringer-Ingelheim Rheumatic Disease Drugs Product Portfolio
  102. 6.17.5 Boehringer-Ingelheim Recent Developments
  103. 6.18 Aprazer
  104. 6.18.1 Aprazer Company Information
  105. 6.18.2 Aprazer Business Overview
  106. 6.18.3 Aprazer Rheumatic Disease Drugs Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Aprazer Rheumatic Disease Drugs Product Portfolio
  108. 6.18.5 Aprazer Recent Developments
7 North America
  1. 7.1 North America Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Rheumatic Disease Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Rheumatic Disease Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Rheumatic Disease Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Rheumatic Disease Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Rheumatic Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Rheumatic Disease Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Rheumatic Disease Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst